(NYSE:NUVB),
SAN DIEGO, March 04, 2026 (GLOBE NEWSWIRE) — Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Nuvation Bio Inc. (NYSE: NUVB). The investigation focuses on whether Nuvation Bio and its executive officers complied with federal securities laws.
What if I purchased Nuvation Bio securities?
If you purchased Nuvation Bio securities and suffered losses on your investment, join our investigation now: Click here to join the investigation.
For more information, contact Jim Baker at jimb@johnsonfistel.com or (619) 814-4471.
There is no cost or obligation to you.
Background of the investigation
On March 2, 2026, Nuvation Bio reported its fourth quarter and full year 2025 financial results and provided additional detail regarding the commercial launch of its oncology therapy IBTROZI (taletrectinib).
During the earnings call, the Company disclosed that approximately 75% of treatment discontinuations in 2025 occurred among later-line patient populations. Management explained that these later-line patients tend to discontinue therapy relatively quickly and are often not treated for multiple quarters, which can impact near-term revenue trends.
The Company also stated that a significant share of early patient starts during the launch occurred in the third-line or later treatment setting, which contributed to the gap between the number of patients starting IBTROZI and net product revenue growth.
Following these disclosures, Nuvation Bio's shares declined sharply.
In light of this disclosure, Johnson Fistel is investigating whether Nuvation Bio complied with the federal securities laws. If you suffered losses from your investment in Nuvation Bio stock, contact Johnson Fistel.
About Johnson Fistel, PLLP | Securities Fraud & Investor Rights
Johnson Fistel, PLLP is a nationally recognized shareholder-rights law firm with offices in California, New York, Georgia, Idaho, and Colorado. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits and also assists foreign investors who purchased shares on U.S. exchanges. To learn more, visit www.johnsonfistel.com.
Attorney advertising.
Past results do not guarantee future outcomes.
Services may be performed by attorneys in any of our offices.
Johnson Fistel, PLLP has paid for the dissemination of this promotional communication, and Frank J. Johnson is the attorney responsible for its content.
Contact
Johnson Fistel, PLLP
501 W. Broadway, Suite 800
San Diego, CA 92101
James Baker, Investor Relations – or – Frank J. Johnson, Esq.
(619) 814-4471 | jimb@johnsonfistel.com | fjohnson@johnsonfistel.com
